Over the course of the forecast period, the APOLA-mediated renal ailment market sale is anticipated to grow at a 4.3% annual rate, from US$ 3779.9 million in 2023 to US$ 5753.9 million in 2033.
This prediction reflects the increasing importance and focus on treating renal disorders caused by the variation of the APOL1 gene. Increased investments and improvements in diagnostic and therapeutic solutions are anticipated in the market as research and development projects pick up steam and awareness of APOL1 Mediated Kidney Disease grows. The projected expansion represents a concerted attempt by the medical community to address this particular type of kidney illness, indicating a turning point in the treatment of renal disease.
There are several advantages to new medication approvals in the chronic renal disease industry. It offers More treatment options for consumers and healthcare providers mean higher profits for pharmaceutical companies. Additionally, it facilitates patient access to care and promotes continued advancements in the field of research and development. The strict regulations imposed on new treatments also guarantee their efficacy and safety. These elements support the market for chronic kidney disease’s anticipated expansion throughout the forecast period.
Get a Sample Copy of the Report:
https://www.futuremarketinsights.com/reports/sample/rep-gb-12115
The market is expected to be fuelled by factors such as the rising prevalence of chronic kidney disease worldwide. The increasing demand for novel treatments to enhance patients’ quality of life is driven by the growing incidence of chronic kidney diseases. According to a 2019 report from the Centers for Disease Control and Prevention, approximately 37 million people in the United States are estimated to have chronic kidney diseases.
The increasing geriatric population, which is susceptible to various diseases including APOL 1 mediated kidney diseases, is a major driver for market growth. Hence, increasing research and development activities in the development of chronic kidney disease drugs are expected to generate new opportunities for market expansion during the forecast period.
AstraZeneca sealed a $330 million licensing agreement in 2018 with Ionis Pharmaceuticals, Inc., a clinical-stage innovator company focused on advanced research for rare diseases based in the United States. This agreement encompassed two pipeline antisense therapies. Notably, one of the licensed therapeutics is an investigational novel antisense drug called AZD2373, designed to target the root cause of APOL1 mediated chronic kidney diseases. Currently in Phase I of clinical trials, AZD2373 shows promise as a potential candidate for the future landscape of APOL1 mediated kidney diseases.
Key Takeaways:
- North America is expected to dominate the market while growing with a CAGR of 4.1% during the forecast period.
- The market in India is projected to witness a CAGR of 4.4% during the forecast period.
- The market in the United Kingdom is expected to grow at a 4.2% CAGR during the forecast period.
- By indication, chronic kidney disease is projected to lead the segment and is estimated to grow with a CAGR of 5.8% during the forecast period.
- The end-stage kidney disease segment is expected to grow with a CAGR of 2.1% throughout the forecast period.
“Increasing focus on research and development for understanding the underlying cause of APOL1 mediated kidney disease and developing targeted therapies is expected to drive market growth over the forecast period,” – comments an analyst at FMI.
Competitive Landscape:
The APOL1 mediated kidney disease market is extremely competitive and consists of various key industry players. These players are heavily investing in the APOL1-mediated kidney disease treatment market.
The key industry players are Vertex Pharmaceuticals Incorporated, Ionis Pharmaceuticals, AstraZeneca, Pfizer Inc., Novartis AG, GlaxoSmithKline plc, Merck & Co., Inc., Sanofi S.A., Johnson & Johnson, AbbVie Inc., Bristol-Myers Squibb Company, Roche Holding AG.
Some recent developments in the market are:
Key market players make use of organic growth strategies like acquisition, tie-ups, mergers, partnerships, and collaboration to enhance their product portfolio. This is expected to fuel the global APOL1-mediated kidney disease market.
- On November 4, 2022, Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) collaborated with basketball Hall-of-Famer Alonzo Mourning to introduce “Power Forward,” an educational initiative. This program aims to increase awareness of APOL1-mediated kidney disease (AMKD) and emphasize the significance of early diagnosis and genetic testing.
- In July 2022, AstraZeneca partnered with the Indian Society of Nephrology to establish the chronic kidney disease academy.
- On March 22, 2022, Vertex Pharmaceuticals Incorporated disclosed the advancement of VX-147 into pivotal development for individuals affected by proteinuric kidney disease caused by two mutations in the APOL1 gene (AMKD).
More Valuable Insights:
Future Market Insights offers an unbiased analysis of the global APOL1-mediated kidney disease market, providing historical data for 2017 to 2022 and forecast statistics from 2023 to 2033.
To understand opportunities in the APOL1-mediated kidney disease market, the market is segmented on the basis of indication and region.
Request Report Methodology:https://www.futuremarketinsights.com/request-report-methodology/rep-gb-12115
Key Segments Profiled:
By Indication:
- Chronic Kidney Disease
- Focal segmental glomerulosclerosis (FSGS)
- Human immunodeficiency virus (HIV)-associated Nephropathy
- Hypertension-associated Kidney Disease
- End-Stage Kidney Disease
By Region:
- North America
- Latin America
- Europe
- Asia Pacific
- Middle East and Africa
Author By:
Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.
Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.
Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
